Krystal Alligood

Krystal spent fifteen years in the pharmaceutical industry at GlaxoSmithKline. Her skills in protein analysis, cell-based assays, and immunoassay design contributed to the discovery and development of Tykerb, an FDA-approved treatment for metastatic breast cancer. Krystal’s areas of expertise include development and validation of immunoassays on ELISA, DELFIA, and MSD platforms in a regulated environment. Her responsibilities include management and execution of PK and biomarker projects supporting preclinical and clinical studies, and preparation of study reports and Standard Operating Procedures.

Krystal has co-authored 18 peer-reviewed publications and several abstracts that have been presented at national and international conferences. Krystal received a B.S. in biology and chemistry from Campbell University in Buies Creek, North Carolina, and an M.S. in Biochemistry from North Carolina State University.